North America Epirubicin Market

The North America epirubicin market is expected to grow from US$ 95,445.28 thousand in 2022 to US$ 1,18,596.58 thousand by 2028; it is estimated to grow at a CAGR of 3.7% from 2022 to 2028.       

Rising FDA Approvals for Cancer Drugs Offers Lucrative Market Opportunities

On June 22, 2022, the US Food and Drug Administration (FDA) granted accelerated approval to the usage of dabrafenib, which is sold under the brand name Tafinlar by Novartis in combination with trametinib that is sold under the brand name Mekinist by Novartis to treat patients, especially pediatric patients above six years of age, with solid metastatic tumors with BRAF V600E mutation. On December 1, 2017, the FDA approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) to treat breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors isoform the HER2 gene (HER2+). On May 27, 2022, the FDA approved Nvolumab, which is sold under the brand name Opdivo by Bristol-Myers Squibb Company, in combination with fluoropyrimidine- and platinum-based chemotherapy and nivolumab in combination with ipilimumab that is sold under the brand name Yervoy by Bristol-Myers Squibb Company for the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients. On March 11, 2022, the FDA approved olaparib that is sold under the brand name Lynparza by AstraZeneca Pharmaceuticals, L.P. for treating breast cancer patients. Further, in May 2021, the FDA granted accelerated approval to combining the immunotherapy drug pembrolizumab (Keytruda) with standard treatments for patients with HER2+ tumors of the esophagus or stomach. Thus, the rising number of FDA approvals is offering lucrative opportunities for the epirubicin market growth. 

Market Overview

The North America epirubicin market is segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2021. The rising prevalence of breast cancer, growing research & development activities, and increasing demand for advanced therapeutic solutions to treat cancer are among the prominent factors propelling the market growth. The increasing prevalence of breast cancer in the US is likely to increase the demand for epirubicin. According to the Centers for Disease Control and Prevention (CDC), every year in the US, ~2,64,000 cases of breast cancer are diagnosed in women and ~2,400 in men. Further, epirubicin is also used to treat bladder cancer. The American Cancer Society estimated that by the end of 2022, there will be 81,180 new cases of bladder cancer. Additionally, the US pharmaceutical market is the largest and the most commercial market in North America; it holds over 45% of the global pharmaceutical market. The majority of the leading global drug manufacturing companies are US-based that are active in the manufacturing of medical devices/diagnostics and consumer products. Thus, the increasing prevalence of cancer in the country is anticipated to boost the US epirubicin market growth during the forecast period.

 North America Epirubicin Market Revenue and Forecast to 2028 (US$ Thousand)

Get more information on this report Request Free Sample PDF

North America Epirubicin Strategic Insights

Strategic insights for the North America Epirubicin provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Epirubicin Report Scope

North America Epirubicin Regional Insights

The geographic scope of the North America Epirubicin refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

  North America Epirubicin Market Segmentation   

The North America epirubicin market is segmented on the basis of dosage, application, distribution channel, and country. Based on dosage, the North America epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held the largest market share in 2022. Based on application, the North America epirubicin market is categorized into breast cancer, liver cancer, bladder cancer, and others. The breast cancer segment held the largest market share in 2022. Based on distribution channel, the North America epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. Based on country, the North America epirubicin market has been categorized into the US, Canada, and Mexico. Further, the US dominated the market in 2022.eva Pharmaceuticals, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Salius Pharma Pvt Ltd, and Teva Pharmaceutical Industries Ltd. are the leading companies operating in the North America epirubicin market.